| Lakeview House Skld Nrsg And Residential Care Fac | |
| 87 Shattuck Street, Haverhill, Massachusetts 01830 | |
| (978) 372-1081 | |
| Name | Lakeview House Skld Nrsg And Residential Care Fac |
|---|---|
| Location | 87 Shattuck Street, Haverhill, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 26 |
| Occupancy Rate | 74.62% |
| Medicare ID (CCN) | 225401 |
| Legal Business Name | Lakeview House Inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1215921747 |
| Organization Name | LAKEVIEW HOUSE INC |
| Address | 87 Shattuck St, Haverhill, MA 01830 |
| Phone Number | 978-372-1081 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan. Latest results of Gero aging studies will be presented at Longevity Therapeutics Conference in San Francisco, January 29-31, 2019.
Tobacco dependence is very common in patients hospitalized with substance use disorders (SUDs) – but most don't receive recommended treatment for tobacco dependence while in the hospital, reports a study in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine
The results of the Home Monitoring of the Eye (HOME) study, conducted in Age-Related Eye Disease Study 2 (AREDS2) clinical centers, executed by the EMMES Corporation and sponsored by Notal Vision Ltd. Tel Aviv, Israel, have been accepted for publication in Ophthalmology.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan. Latest results of Gero aging studies will be presented at Longevity Therapeutics Conference in San Francisco, January 29-31, 2019.
Tobacco dependence is very common in patients hospitalized with substance use disorders (SUDs) – but most don't receive recommended treatment for tobacco dependence while in the hospital, reports a study in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine
The results of the Home Monitoring of the Eye (HOME) study, conducted in Age-Related Eye Disease Study 2 (AREDS2) clinical centers, executed by the EMMES Corporation and sponsored by Notal Vision Ltd. Tel Aviv, Israel, have been accepted for publication in Ophthalmology.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 5.81 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.33 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 48.61 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.77 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 36.84 | 14.2 |